









Markets
/
Stocks
/
nasdaq-avdl
/

Avadel Pharmaceuticals PLC

AVDL

18.830USD

+0.130+0.70%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.83BMarket Cap

LossP/E TTM



Avadel Pharmaceuticals PLC

18.830

+0.130+0.70%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Avadel Pharmaceuticals PLC

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Avadel Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking

43 / 159

Overall Ranking

100 / 4608

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Hold

Current Rating

19.889

Target Price

+6.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Avadel Pharmaceuticals PLC Highlights

StrengthsRisks

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Undervalued

The company’s latest PE is -10821.84, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 84.18M shares, decreasing 21.36% quarter-over-quarter.

Held by Brandes Investmen

Star Investor Brandes Investmen holds 6.49M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 9.08, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 77.47M, representing a year-over-year increase of 54.86%, while its net profit experienced a year-over-year increase of 100.76%.

Score

Industry at a Glance

Previous score

9.08

Change



Financials

8.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Avadel Pharmaceuticals PLC's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.44, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -10821.84, which is -99.97% below the recent high of -2.80 and -0.69% above the recent low of -10896.55.

Score

Industry at a Glance

Previous score

7.44

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 6.20, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Avadel Pharmaceuticals PLC is 20.00, with a high of 22.00 and a low of 18.50.

Score

Industry at a Glance

Previous score

6.20

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Hold

Current Rating

19.889

Target Price

+6.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Avadel Pharmaceuticals PLC

AVDL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 9.53, which is higher than the Pharmaceuticals industry's average of 7.38. Sideways: Currently, the stock price is trading between the resistance level at 20.49 and the support level at 15.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.35

Change

0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.110

Neutral

RSI(14)

75.323

Buy

STOCH(KDJ)(9,3,3)

36.498

Neutral

ATR(14)

0.172

High Vlolatility

CCI(14)

28.636

Neutral

Williams %R

38.983

Buy

TRIX(12,20)

0.947

Sell

StochRSI(14)

19.562

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

18.778

Buy

MA10

18.833

Sell

MA20

18.009

Buy

MA50

16.318

Buy

MA100

13.938

Buy

MA200

11.219

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 86.25%, representing a quarter-over-quarter decrease of 4.41%. The largest institutional shareholder is Brandes Investmen, holding a total of 6.49M shares, representing 6.64% of shares outstanding, with 195.06% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

11.13M

-18.10%

Brandes Investment Partners, L.P.

Star Investors

6.49M

+14.48%

Two Seas Capital LP

6.16M

+24.43%

BlackRock Institutional Trust Company, N.A.

5.98M

+27.56%

The Vanguard Group, Inc.

Star Investors

5.54M

+42.73%

Tontine Asset Management, LLC

5.18M

-15.51%

Polar Capital LLP

4.00M

-8.19%

Kotler (Kevin)

3.72M

-21.37%

Vivo Capital, LLC

2.68M

Wealth Effects LLC

2.35M

-0.60%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 6.30, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.